

Amendments to the Claims

The claims in this listing will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-7. (Canceled)

8. (Currently Amended) A method of increasing apoptotic effect of cytostatics after chemotherapy comprising administering a 5-substituted nucleoside comprising (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), ~~a protected form~~, salt, prodrug or mixture thereof, the administering being without administration of a cytostatic, during a recovery phase after a cytostatic chemotherapy cycle.


9. (Currently Amended) The method of claim 8, wherein the cytostatic chemotherapy cycle includes administration of a cytostatic and a 5-substituted nucleoside comprising BVDU, ~~a protected form~~, salt, prodrug, or mixture thereof.

10. (Currently Amended) The method of claim 9 wherein during the cytostatic chemotherapy cycle, administered amounts of cytostatic are increased over a period of the cytostatic chemotherapy cycle, and the administered amount of BVDU, ~~protected form~~, salt, prodrug, or combination thereof is constant.


11. (Previously Presented) The method of claim 10 wherein the recovery phase has a duration of from 3 to 10 days.

12. (Previously Presented) The method of claim 10 wherein the chemotherapy cycle has a duration of from 8 to 30 days.


13. (Previously Presented) The method of claim 8 wherein the 5-substituted nucleoside administered during the recovery phase comprises a compound of the general formula I:



14. (Previously Presented) The method of claim 9 wherein the 5-substituted nucleoside administered during the recovery phase comprises a compound of the general formula I:



15. (Previously Presented) The method of claim 14 wherein the 5-substituted nucleoside administered during the chemotherapy cycle comprises a compound of the general formula I:



16. (Previously Presented) The method of claim 8 wherein the administration provides a 5-substituted nucleoside blood concentration between 0.02 and 50 $\mu\text{g/ml}$.

17. (Previously Presented) The method of claim 9 wherein the cytostatic comprises doxorubicin, mitoxantrone, mitomycin C, or methotrexate.

18. (Previously Presented) The method of claim 13 wherein the administration provides a 5-substituted nucleoside blood concentration between 0.02 and 50 µg/ml during the recovery phase.

19. (Previously Presented) The method of claim 14 wherein the administration provides a 5-substituted nucleoside blood concentration between 0.02 and 50 µg/ml during the recovery phase.

20. (Previously Presented) The method of claim 15 wherein the cytostatic comprises doxorubicin, mitoxantrone, mitomycin C, or methotrexate.

21. (Previously Presented) The method of claim 15 wherein the administration provides a 5-substituted nucleoside blood concentration between 0.02 and 50 µg/ml during the recovery phase.

22. (Previously Presented) The method of claim 15 wherein the administration provides a 5-substituted nucleoside blood concentration between 0.02 and 50 µg/ml during the cytostatic chemotherapy cycle.

23. (Previously Presented) The method of claim 14 wherein the administration provides a 5-substituted nucleoside blood concentration between 0.02 and 50 µg/ml during the recovery phase.

24. (Previously Presented) The method of claim 15 wherein the recovery phase has a duration of from 3 to 10 days.

25. (Previously Presented) The method of claim 24 wherein the chemotherapy cycle has a duration of from 8 to 30 days.

26. (Previously Presented) The method of claim 15 wherein the chemotherapy cycle has a duration of from 8 to 30 days.